Janine Pilcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Janine Pilcher has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Richard Beasley
Medical Research Institute of New Zealand, Wellington, New Zealand
12 shared publications - Mark Weatherall
University of Otago Wellington, Wellington, New Zealand
10 shared publications Mitesh Patel
Medical Research Institute of New Zealand, Wellington, New Zealand
5 shared publications- Alison Pritchard
Medical Research Institute of New Zealand, Wellington, New Zealand
3 shared publications - Dominick Shaw
Department of Respiratory Sciences, University of Leicester, Leicester, Leicestershire, UK
3 shared publications Peter Black
University of Auckland, Auckland, New Zealand
3 shared publications
Latest Publications
- 28 March 2025
- Published by Pasifika Medical Association Group in New Zealand Medical Journal
- Vol. 138 (1612) , 21-46
Patterns and experiences of smoking, electronic cigarettes (vapes) and heated tobacco use among people who smoke or who recently quit
Aim: The aim of this study is to understand patterns and experiences of smoking and electronic cigarette use, as well as related attitudes and behaviours among adults in Aotearoa New Zealand who smoke or recently stopped smoking. methods: We analysed data from the Evidence for Achieving Smokefree Aotearoa Equitably/International Tobacco Control New Zealand Survey (N=1,230), conducted between November 2020 and February 2021. results: Among people who smoked, 77.5% (95% confidence interval [CI] 74.0–80.8%) reported regretting having started smoking, 73.6% (95% CI 69.5–77.4) intended to quit, 87.3% (95% CI 84.1–89.9) reported being addicted to smoking and 86.3% (95% CI 83.3–88.8) had tried to quit smoking in the past. Among people who smoked, 24.8% (95% CI 21.3–28.6) used electronic cigarettes (ECs) daily and 4.6% (95% CI 3.3–6.6) used heated tobacco products (HTPs) daily. Among people who had recently stopped smoking, 33.4% (95% CI 25.6–42.2) used ECs daily and less than 1% used HTPs daily. conclusion: High levels of regret for starting smoking, addiction and intent to quit smoking highlight the importance of implementing effective and equitable smokefree measures to prevent people from starting to smoke and to support people to stop smoking.
- 28 March 2025
- Published by Pasifika Medical Association Group in New Zealand Medical Journal
- Vol. 138 (1612) , 21-46
Patterns and experiences of smoking, electronic cigarettes (vapes) and heated tobacco use among people who smoke or who recently quit
Aim: The aim of this study is to understand patterns and experiences of smoking and electronic cigarette use, as well as related attitudes and behaviours among adults in Aotearoa New Zealand who smoke or recently stopped smoking. methods: We analysed data from the Evidence for Achieving Smokefree Aotearoa Equitably/International Tobacco Control New Zealand Survey (N=1,230), conducted between November 2020 and February 2021. results: Among people who smoked, 77.5% (95% confidence interval [CI] 74.0–80.8%) reported regretting having started smoking, 73.6% (95% CI 69.5–77.4) intended to quit, 87.3% (95% CI 84.1–89.9) reported being addicted to smoking and 86.3% (95% CI 83.3–88.8) had tried to quit smoking in the past. Among people who smoked, 24.8% (95% CI 21.3–28.6) used electronic cigarettes (ECs) daily and 4.6% (95% CI 3.3–6.6) used heated tobacco products (HTPs) daily. Among people who had recently stopped smoking, 33.4% (95% CI 25.6–42.2) used ECs daily and less than 1% used HTPs daily. conclusion: High levels of regret for starting smoking, addiction and intent to quit smoking highlight the importance of implementing effective and equitable smokefree measures to prevent people from starting to smoke and to support people to stop smoking.
- 24 January 2025
- Published by Pasifika Medical Association Group in New Zealand Medical Journal
- Vol. 138 (1608) , 40-83
Support for and likely impacts of endgame measures in the Smokefree Aotearoa Action Plan: findings from the 2020–2021 International Tobacco Control New Zealand (EASE) surveys
Aim: In February 2024, the Aotearoa New Zealand Government repealed legislation to mandate very low nicotine cigarettes (VLNCs), greatly reduce the number of tobacco retailers and disallow sale of tobacco products to people born after 2008 (smokefree generation). We investigated acceptability and likely impacts of these measures among people who smoke or who recently (≤2 years) quit smoking. method: We analysed data from 1,230 participants from Wave 3 (conducted in late 2020 and early 2021) and 615 participants from Wave 3.5 (conducted in June/July 2021) of the New Zealand arm of the International Tobacco Control (ITC) Policy Evaluation Project. Data were weighted to represent the national population of people who smoke and who recently quit smoking. results: Support (excluding “Don’t know” responses) was 82.7% (95% confidence interval 77.9, 86.6) for a smokefree generation, 75.0% (95% CI 71.4, 78.3) for mandated VLNCs and 35.2% (95% CI 31.7, 38.9) for retailer reduction. Support was mostly similar by ethnicity, gender, age and evidence of financial hardship, but was higher among people who had recently quit smoking. Around half of the participants who smoked anticipated quitting completely, switching to vaping or cutting down the amount they smoke if mandated VLNCs or substantial retailer reductions were introduced. If VLNCs were mandated, 19% of people who smoked stated they would carry on smoking like they do now and find a way to get the cigarettes or tobacco they want to smoke. conclusion: Support for and anticipated actions in response to the smokefree legislation measures call into question the Government’s decision to repeal them.
- 24 January 2025
- Published by Pasifika Medical Association Group in New Zealand Medical Journal
- Vol. 138 (1608) , 40-83
Support for and likely impacts of endgame measures in the Smokefree Aotearoa Action Plan: findings from the 2020–2021 International Tobacco Control New Zealand (EASE) surveys
Aim: In February 2024, the Aotearoa New Zealand Government repealed legislation to mandate very low nicotine cigarettes (VLNCs), greatly reduce the number of tobacco retailers and disallow sale of tobacco products to people born after 2008 (smokefree generation). We investigated acceptability and likely impacts of these measures among people who smoke or who recently (≤2 years) quit smoking. method: We analysed data from 1,230 participants from Wave 3 (conducted in late 2020 and early 2021) and 615 participants from Wave 3.5 (conducted in June/July 2021) of the New Zealand arm of the International Tobacco Control (ITC) Policy Evaluation Project. Data were weighted to represent the national population of people who smoke and who recently quit smoking. results: Support (excluding “Don’t know” responses) was 82.7% (95% confidence interval 77.9, 86.6) for a smokefree generation, 75.0% (95% CI 71.4, 78.3) for mandated VLNCs and 35.2% (95% CI 31.7, 38.9) for retailer reduction. Support was mostly similar by ethnicity, gender, age and evidence of financial hardship, but was higher among people who had recently quit smoking. Around half of the participants who smoked anticipated quitting completely, switching to vaping or cutting down the amount they smoke if mandated VLNCs or substantial retailer reductions were introduced. If VLNCs were mandated, 19% of people who smoked stated they would carry on smoking like they do now and find a way to get the cigarettes or tobacco they want to smoke. conclusion: Support for and anticipated actions in response to the smokefree legislation measures call into question the Government’s decision to repeal them.
- Open Access
- 28 March 2024
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 26 (10) , 1322-1330
Commercial Tobacco Endgame Goals: Early Experiences From Six Countries
Introduction: Tobacco use is a major threat to health globally. A number of countries have adopted “endgame goals” to minimize smoking prevalence. The INSPIRED project aims to describe and compare the experiences of the first six countries to adopt an endgame goal. Aims and Methods: Data were collected on the initial experiences of endgame goals in Canada, Finland, Ireland, New Zealand (Aotearoa), Scotland, and Sweden up to 2018. Information was collated on the nature of the endgame goals, associated interventions and strategies, potential enablers and barriers, and perceived advantages and disadvantages. Results: The INSPIRED countries had relatively low smoking prevalences and moderate-to-strong smoke-free policies. Their endgame goals aimed for smoking prevalences of 5% or less. Target dates ranged from 2025 to 2035. Except for New Zealand (Aotearoa), all countries had an action plan to support their goal by 2018. However, none of the plans incorporated specific endgame measures. Lack of progress in reducing inequities was a key concern, despite the consideration of equity in all of the country’s goals and/or action plans. Experience with endgame goals was generally positive; however, participants thought additional interventions would be required to equitably meet their endgame goal. Conclusions: There was variation in the nature and approach to endgame goals. This suggests that countries should consider adopting endgame goals and strategies to suit their social, cultural, and political contexts. The experiences of the INSPIRED countries suggest that further and more significant interventions will be required for the timely and equitable achievement of endgame goals. Implications: By 2018, six countries (Canada, Finland, Ireland, New Zealand (Aotearoa), Scotland, and Sweden) had introduced government-endorsed “endgame goals,” to rapidly reduce smoking prevalence to very low levels by a specified date. The nature and implementation of endgame goals were variable. Early experiences with the goals were generally positive, but progress in reducing smoking prevalence was insufficient, particularly for priority groups. This finding suggests more significant interventions (“endgame interventions”) and measures to reduce inequities need to be implemented to achieve endgame goals. Variation in the nature and experience of endgame goals demonstrates the importance of designing endgame strategies that suit distinct social, cultural, and political contexts.
- 28 March 2024
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 26 (10) , 1322-1330
Open AccessCommercial Tobacco Endgame Goals: Early Experiences From Six Countries
Introduction: Tobacco use is a major threat to health globally. A number of countries have adopted “endgame goals” to minimize smoking prevalence. The INSPIRED project aims to describe and compare the experiences of the first six countries to adopt an endgame goal. Aims and Methods: Data were collected on the initial experiences of endgame goals in Canada, Finland, Ireland, New Zealand (Aotearoa), Scotland, and Sweden up to 2018. Information was collated on the nature of the endgame goals, associated interventions and strategies, potential enablers and barriers, and perceived advantages and disadvantages. Results: The INSPIRED countries had relatively low smoking prevalences and moderate-to-strong smoke-free policies. Their endgame goals aimed for smoking prevalences of 5% or less. Target dates ranged from 2025 to 2035. Except for New Zealand (Aotearoa), all countries had an action plan to support their goal by 2018. However, none of the plans incorporated specific endgame measures. Lack of progress in reducing inequities was a key concern, despite the consideration of equity in all of the country’s goals and/or action plans. Experience with endgame goals was generally positive; however, participants thought additional interventions would be required to equitably meet their endgame goal. Conclusions: There was variation in the nature and approach to endgame goals. This suggests that countries should consider adopting endgame goals and strategies to suit their social, cultural, and political contexts. The experiences of the INSPIRED countries suggest that further and more significant interventions will be required for the timely and equitable achievement of endgame goals. Implications: By 2018, six countries (Canada, Finland, Ireland, New Zealand (Aotearoa), Scotland, and Sweden) had introduced government-endorsed “endgame goals,” to rapidly reduce smoking prevalence to very low levels by a specified date. The nature and implementation of endgame goals were variable. Early experiences with the goals were generally positive, but progress in reducing smoking prevalence was insufficient, particularly for priority groups. This finding suggests more significant interventions (“endgame interventions”) and measures to reduce inequities need to be implemented to achieve endgame goals. Variation in the nature and experience of endgame goals demonstrates the importance of designing endgame strategies that suit distinct social, cultural, and political contexts.
- Open Access
- 7 May 2020
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 20 (1) , 1-10
The effect of 50% oxygen on PtCO2 in patients with stable COPD, bronchiectasis, and neuromuscular disease or kyphoscoliosis: randomised cross-over trials
Background: High-concentration oxygen therapy causes increased arterial partial pressure of carbon dioxide (PaCO2) in patients with COPD, asthma, pneumonia, obesity and acute lung injury. The objective of these studies was to investigate whether this physiological response to oxygen therapy occurs in stable patients with neuromuscular disease or kyphoscoliosis, and bronchiectasis.Methods: Three randomised cross-over trials recruited stable patients with neuromuscular disease or kyphoscoliosis (n = 20), bronchiectasis (n = 24), and COPD (n = 24). Participants were randomised to receive 50% oxygen and 21% oxygen (air), each for 30 min, in randomly assigned order. The primary outcome was transcutaneous partial pressure of carbon dioxide (PtCO2) at 30 min. The primary analysis was a mixed linear model.Results: Sixty six of the 68 participants had baseline PtCO2values < 45 mmHg. The intervention baseline adjusted PtCO2difference (95% CI) between oxygen and room air after 30 min was 0.2 mmHg (− 0.4 to 0.9),P = 0.40; 0.5 mmHg (− 0.2 to 1.2),P = 0.18; and 1.3 mmHg (0.7 to 1.8),P < 0.001, in the neuromuscular/kyphoscoliosis, bronchiectasis and COPD participants respectively.Conclusions: The small increase in PtCO2in the stable COPD patients with high-concentration oxygen therapy contrasts with the marked increases in PaCO2seen in the setting of acute exacerbations of COPD. This suggests that the model of studying the effects of high-concentration oxygen therapy in patients with stable respiratory disease is not generalisable to the use of oxygen therapy in the acute clinical setting. Appropriate studies of high-concentration compared to titrated oxygen in acute clinical settings are needed to determine if there is a risk of oxygen-induced hypercapnia in patients with neuromuscular disease, kyphoscoliosis or bronchiectasis.Trial registration: Australian New Zealand Clinical Trials RegistryACTRN12615000970549Registered 16/9/15,ACTRN12615000971538Registered 16/9/15 andACTRN12615001056583Registered 7/10/15.
- 7 May 2020
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 20 (1) , 1-10
Open AccessThe effect of 50% oxygen on PtCO2 in patients with stable COPD, bronchiectasis, and neuromuscular disease or kyphoscoliosis: randomised cross-over trials
Background: High-concentration oxygen therapy causes increased arterial partial pressure of carbon dioxide (PaCO2) in patients with COPD, asthma, pneumonia, obesity and acute lung injury. The objective of these studies was to investigate whether this physiological response to oxygen therapy occurs in stable patients with neuromuscular disease or kyphoscoliosis, and bronchiectasis.Methods: Three randomised cross-over trials recruited stable patients with neuromuscular disease or kyphoscoliosis (n = 20), bronchiectasis (n = 24), and COPD (n = 24). Participants were randomised to receive 50% oxygen and 21% oxygen (air), each for 30 min, in randomly assigned order. The primary outcome was transcutaneous partial pressure of carbon dioxide (PtCO2) at 30 min. The primary analysis was a mixed linear model.Results: Sixty six of the 68 participants had baseline PtCO2values < 45 mmHg. The intervention baseline adjusted PtCO2difference (95% CI) between oxygen and room air after 30 min was 0.2 mmHg (− 0.4 to 0.9),P = 0.40; 0.5 mmHg (− 0.2 to 1.2),P = 0.18; and 1.3 mmHg (0.7 to 1.8),P < 0.001, in the neuromuscular/kyphoscoliosis, bronchiectasis and COPD participants respectively.Conclusions: The small increase in PtCO2in the stable COPD patients with high-concentration oxygen therapy contrasts with the marked increases in PaCO2seen in the setting of acute exacerbations of COPD. This suggests that the model of studying the effects of high-concentration oxygen therapy in patients with stable respiratory disease is not generalisable to the use of oxygen therapy in the acute clinical setting. Appropriate studies of high-concentration compared to titrated oxygen in acute clinical settings are needed to determine if there is a risk of oxygen-induced hypercapnia in patients with neuromuscular disease, kyphoscoliosis or bronchiectasis.Trial registration: Australian New Zealand Clinical Trials RegistryACTRN12615000970549Registered 16/9/15,ACTRN12615000971538Registered 16/9/15 andACTRN12615001056583Registered 7/10/15.
- Open Access
- 9 January 2020
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 20 (1) , 1-9
A multicentre prospective observational study comparing arterial blood gas values to those obtained by pulse oximeters used in adult patients attending Australian and New Zealand hospitals
Background: Pulse oximetry is widely used in the clinical setting. The purpose of this validation study was to investigate the level of agreement between oxygen saturations measured by pulse oximeter (SpO2) and arterial blood gas (SaO2) in a range of oximeters in clinical use in Australia and New Zealand. Methods: Paired SpO2 and SaO2 measurements were collected from 400 patients in one Australian and two New Zealand hospitals. The ages of the patients ranged from 18 to 95 years. Bias and limits of agreement were estimated. Sensitivity and specificity for detecting hypoxaemia, defined as SaO2 < 90%, were also estimated. Results: The majority of participants were recruited from the Outpatient, Ward or High Dependency Unit setting. Bias, oximeter-measured minus arterial blood gas-measured oxygen saturation, was − 1.2%, with limits of agreement − 4.4 to 2.0%. SpO2 was at least 4% lower than SaO2 for 10 (2.5%) of the participants and SpO2 was at least 4% higher than the SaO2 in 3 (0.8%) of the participants. None of the participants with a SpO2 ≥ 92% were hypoxaemic, defined as SaO2 < 90%. There were no clinically significant differences in oximetry accuracy in relation to clinical characteristics or oximeter brand. Conclusions: In the majority of the participants, pulse oximetry was an accurate method to assess SaO2 and had good performance in detecting hypoxaemia. However, in a small proportion of participants, differences between SaO2 and SpO2 could have clinical relevance in terms of patient monitoring and management. A SpO2 ≥ 92% indicates that hypoxaemia, defined as a SaO2 < 90%, is not present. Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN12614001257651). Date of registration: 2/12/2014.
- 9 January 2020
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 20 (1) , 1-9
Open AccessA multicentre prospective observational study comparing arterial blood gas values to those obtained by pulse oximeters used in adult patients attending Australian and New Zealand hospitals
Background: Pulse oximetry is widely used in the clinical setting. The purpose of this validation study was to investigate the level of agreement between oxygen saturations measured by pulse oximeter (SpO2) and arterial blood gas (SaO2) in a range of oximeters in clinical use in Australia and New Zealand. Methods: Paired SpO2 and SaO2 measurements were collected from 400 patients in one Australian and two New Zealand hospitals. The ages of the patients ranged from 18 to 95 years. Bias and limits of agreement were estimated. Sensitivity and specificity for detecting hypoxaemia, defined as SaO2 < 90%, were also estimated. Results: The majority of participants were recruited from the Outpatient, Ward or High Dependency Unit setting. Bias, oximeter-measured minus arterial blood gas-measured oxygen saturation, was − 1.2%, with limits of agreement − 4.4 to 2.0%. SpO2 was at least 4% lower than SaO2 for 10 (2.5%) of the participants and SpO2 was at least 4% higher than the SaO2 in 3 (0.8%) of the participants. None of the participants with a SpO2 ≥ 92% were hypoxaemic, defined as SaO2 < 90%. There were no clinically significant differences in oximetry accuracy in relation to clinical characteristics or oximeter brand. Conclusions: In the majority of the participants, pulse oximetry was an accurate method to assess SaO2 and had good performance in detecting hypoxaemia. However, in a small proportion of participants, differences between SaO2 and SpO2 could have clinical relevance in terms of patient monitoring and management. A SpO2 ≥ 92% indicates that hypoxaemia, defined as a SaO2 < 90%, is not present. Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN12614001257651). Date of registration: 2/12/2014.
- Open Access
- 3 October 2018
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 18 (1) , 1-9
Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial
In exacerbations of chronic obstructive pulmonary disease, administration of high concentrations of oxygen may cause hypercapnia and increase mortality compared with oxygen titrated, if required, to achieve an oxygen saturation of 88–92%. Optimally titrated oxygen regimens require two components: titrated supplemental oxygen to achieve the target oxygen saturation and, if required, bronchodilators delivered by air-driven nebulisation. The effect of repeated air vs oxygen-driven bronchodilator nebulisation in acute exacerbations of chronic obstructive pulmonary disease is unknown. We aimed to compare the effects of air versus oxygen-driven bronchodilator nebulisation on arterial carbon dioxide tension in exacerbations of chronic obstructive pulmonary disease. A parallel group double-blind randomised controlled trial in 90 hospital in-patients with an acute exacerbation of COPD. Participants were randomised to receive two 2.5 mg salbutamol nebulisers, both driven by air or oxygen at 8 L/min, each delivered over 15 min with a 5 min interval in-between. The primary outcome measure was the transcutaneous partial pressure of carbon dioxide at the end of the second nebulisation (35 min). The primary analysis used a mixed linear model with fixed effects of the baseline PtCO2, time, the randomised intervention, and a time by intervention interaction term; to estimate the difference between randomised treatments at 35 min. Analysis was by intention-to-treat. Oxygen-driven nebulisation was terminated in one participant after 27 min when the PtCO2 rose by > 10 mmHg, a predefined safety criterion. The mean (standard deviation) change in PtCO2 at 35 min was 3.4 (1.9) mmHg and 0.1 (1.4) mmHg in the oxygen and air groups respectively, difference (95% confidence interval) 3.3 mmHg (2.7 to 3.9), p < 0.001. The proportion of patients with a PtCO2 change ≥4 mmHg during the intervention was 18/45 (40%) and 0/44 (0%) for oxygen and air groups respectively. Oxygen-driven nebulisation leads to an increase in PtCO2 in exacerbations of COPD. We propose that air-driven bronchodilator nebulisation is preferable to oxygen-driven nebulisation in exacerbations of COPD. Australian New Zealand Clinical Trials Registry number ACTRN12615000389505 . Registration confirmed on 28/4/15.
- 3 October 2018
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 18 (1) , 1-9
Open AccessOxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial
In exacerbations of chronic obstructive pulmonary disease, administration of high concentrations of oxygen may cause hypercapnia and increase mortality compared with oxygen titrated, if required, to achieve an oxygen saturation of 88–92%. Optimally titrated oxygen regimens require two components: titrated supplemental oxygen to achieve the target oxygen saturation and, if required, bronchodilators delivered by air-driven nebulisation. The effect of repeated air vs oxygen-driven bronchodilator nebulisation in acute exacerbations of chronic obstructive pulmonary disease is unknown. We aimed to compare the effects of air versus oxygen-driven bronchodilator nebulisation on arterial carbon dioxide tension in exacerbations of chronic obstructive pulmonary disease. A parallel group double-blind randomised controlled trial in 90 hospital in-patients with an acute exacerbation of COPD. Participants were randomised to receive two 2.5 mg salbutamol nebulisers, both driven by air or oxygen at 8 L/min, each delivered over 15 min with a 5 min interval in-between. The primary outcome measure was the transcutaneous partial pressure of carbon dioxide at the end of the second nebulisation (35 min). The primary analysis used a mixed linear model with fixed effects of the baseline PtCO2, time, the randomised intervention, and a time by intervention interaction term; to estimate the difference between randomised treatments at 35 min. Analysis was by intention-to-treat. Oxygen-driven nebulisation was terminated in one participant after 27 min when the PtCO2 rose by > 10 mmHg, a predefined safety criterion. The mean (standard deviation) change in PtCO2 at 35 min was 3.4 (1.9) mmHg and 0.1 (1.4) mmHg in the oxygen and air groups respectively, difference (95% confidence interval) 3.3 mmHg (2.7 to 3.9), p < 0.001. The proportion of patients with a PtCO2 change ≥4 mmHg during the intervention was 18/45 (40%) and 0/44 (0%) for oxygen and air groups respectively. Oxygen-driven nebulisation leads to an increase in PtCO2 in exacerbations of COPD. We propose that air-driven bronchodilator nebulisation is preferable to oxygen-driven nebulisation in exacerbations of COPD. Australian New Zealand Clinical Trials Registry number ACTRN12615000389505 . Registration confirmed on 28/4/15.
- Open Access
- 1 October 2016
- Published by Elsevier in Respiratory Medicine
- Vol. 119, 115-121
Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma
- 1 October 2016
- Published by Elsevier in Respiratory Medicine
- Vol. 119, 115-121
Open AccessRandomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma
- 2 May 2016
- Published by Wiley in Respirology
- Vol. 21 (5) , 968-969
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma – Reply
- 2 May 2016
- Published by Wiley in Respirology
- Vol. 21 (5) , 968-969
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma – Reply
- 21 February 2016
- Published by Wiley in Respirology
- Vol. 21 (5) , 858-866
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
Background and objectiveThe optimal management of people with asthma with a significant smoking history is uncertain. The aim of this study was to determine whether the efficacy/safety profile of single combination inhaled corticosteroid (ICS)/long acting beta-agonist (LABA) inhaler maintenance and reliever therapy is influenced by smoking status. MethodsWe undertook secondary analyses from an open-label 24-week randomized study of 303 high risk adult asthma patients randomized to budesonide/formoterol 200/6-mu g-metred dose inhaler for maintenance (two actuations twice daily) and either budesonide/formoterol 200/6-mu g-metred dose inhaler one actuation (single ICS/LABA maintenance and reliever therapy (SMART)' regimen) or salbutamol 100 mu g 1-2 actuations for symptom relief (Standard' regimen). Smoking status was classified in to three groups, as current', ex' or never', and a smoking/treatment interaction term tested for each outcome variable. The primary outcome variable was number of participants with at least one severe exacerbation. ResultsThere were 59 current, 97 ex and 147 never smokers included in the analyses. The smoking status/treatment interaction term was not statistically significant for any of the outcome measures. With adjustment for smoking status, the number of participants with severe exacerbations was lower with the SMART regimen (OR 0.45, 95% CI: 0.26-0.77, P=0.004; P value for interaction between smoking status and treatment 0.29). ConclusionWe conclude that the favourable safety/efficacy profile of the SMART regimen applies to patients with high risk asthma, irrespective of smoking status. This study has shown that the favourable efficacy/safety profile of single combination-inhaled corticosteroid/long acting beta-agonist inhaler maintenance and reliever therapy regimen in adult patients with high risk asthma is not influenced by smoking status.
- 21 February 2016
- Published by Wiley in Respirology
- Vol. 21 (5) , 858-866
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
Background and objectiveThe optimal management of people with asthma with a significant smoking history is uncertain. The aim of this study was to determine whether the efficacy/safety profile of single combination inhaled corticosteroid (ICS)/long acting beta-agonist (LABA) inhaler maintenance and reliever therapy is influenced by smoking status. MethodsWe undertook secondary analyses from an open-label 24-week randomized study of 303 high risk adult asthma patients randomized to budesonide/formoterol 200/6-mu g-metred dose inhaler for maintenance (two actuations twice daily) and either budesonide/formoterol 200/6-mu g-metred dose inhaler one actuation (single ICS/LABA maintenance and reliever therapy (SMART)' regimen) or salbutamol 100 mu g 1-2 actuations for symptom relief (Standard' regimen). Smoking status was classified in to three groups, as current', ex' or never', and a smoking/treatment interaction term tested for each outcome variable. The primary outcome variable was number of participants with at least one severe exacerbation. ResultsThere were 59 current, 97 ex and 147 never smokers included in the analyses. The smoking status/treatment interaction term was not statistically significant for any of the outcome measures. With adjustment for smoking status, the number of participants with severe exacerbations was lower with the SMART regimen (OR 0.45, 95% CI: 0.26-0.77, P=0.004; P value for interaction between smoking status and treatment 0.29). ConclusionWe conclude that the favourable safety/efficacy profile of the SMART regimen applies to patients with high risk asthma, irrespective of smoking status. This study has shown that the favourable efficacy/safety profile of single combination-inhaled corticosteroid/long acting beta-agonist inhaler maintenance and reliever therapy regimen in adult patients with high risk asthma is not influenced by smoking status.
- Open Access
- 6 November 2015
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 2 (1) , e000097
Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use
Background Electronic monitoring of inhaled asthma therapy is suggested as the ‘gold standard’ for measuring patterns of medication use in clinical trials. The SmartTurbo (Adherium (NZ) Ltd, Auckland, New Zealand) is an electronic monitor for use with a turbuhaler device (AstraZeneca, UK). The aim of this study was to determine the accuracy of the SmartTurbo in recording Symbicort actuations over a 12-week period of use. Methods Twenty SmartTurbo monitors were attached to the base of 20 Symbicort turbuhalers. Bench testing in a research facility was undertaken on days 0, 5, 6, 7, 8, 9, 14, 21, 28, 56 and 84. Patterns of ‘low-use’ (2 sets of 2 actuations on the same day) and ‘high-use’ (2 sets of 8 actuations on the same day) were performed. The date and time of actuations were recorded in a paper diary and compared with data uploaded from the SmartTurbo monitors. Results 2800 actuations were performed. Monitor sensitivity was 99.9% with a lower 97.5% confidence bound of 99.6%. The positive predictive value was 99.9% with a 97.5% lower confidence bound of 99.7%. Accuracy was not affected by whether the pattern of inhaler use was low or high, or whether there was a delay in uploading the actuation data. Conclusions The SmartTurbo monitor is highly accurate in recording and retaining electronic data in this 12-week bench study. It can be recommended for use in clinical trial settings, in which quality control systems are incorporated into study protocols to ensure accurate data acquisition.
- 6 November 2015
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 2 (1) , e000097
Open AccessThree-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use
Background Electronic monitoring of inhaled asthma therapy is suggested as the ‘gold standard’ for measuring patterns of medication use in clinical trials. The SmartTurbo (Adherium (NZ) Ltd, Auckland, New Zealand) is an electronic monitor for use with a turbuhaler device (AstraZeneca, UK). The aim of this study was to determine the accuracy of the SmartTurbo in recording Symbicort actuations over a 12-week period of use. Methods Twenty SmartTurbo monitors were attached to the base of 20 Symbicort turbuhalers. Bench testing in a research facility was undertaken on days 0, 5, 6, 7, 8, 9, 14, 21, 28, 56 and 84. Patterns of ‘low-use’ (2 sets of 2 actuations on the same day) and ‘high-use’ (2 sets of 8 actuations on the same day) were performed. The date and time of actuations were recorded in a paper diary and compared with data uploaded from the SmartTurbo monitors. Results 2800 actuations were performed. Monitor sensitivity was 99.9% with a lower 97.5% confidence bound of 99.6%. The positive predictive value was 99.9% with a 97.5% lower confidence bound of 99.7%. Accuracy was not affected by whether the pattern of inhaler use was low or high, or whether there was a delay in uploading the actuation data. Conclusions The SmartTurbo monitor is highly accurate in recording and retaining electronic data in this 12-week bench study. It can be recommended for use in clinical trial settings, in which quality control systems are incorporated into study protocols to ensure accurate data acquisition.